Medical/Pharmaceuticals

Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit

SUZHOU, China, Jan. 31, 2024 /PRNewswire/ -- Recently, Crystal Formulations Services (CFS), the CDMO Business Unit of Crystal Pharmatech has achieved a significant milestone by successfully passing the on-site audit conducted by the European Qualified Person (QP), evaluating its GMP quality syste...

2024-01-31 21:00 1804

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

-  First manufacturing run successful for MFG7 facility at the Ireland site -  Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Researc...

2024-01-31 17:31 3255

IGIN: the first innovative device for automatic glove fitting, is now launching a pre-sale

DUBAI, UAE, Jan. 31, 2024 /PRNewswire/ -- Approximately 99,000 Americans die each year in hospitals due to infections acquired there, according to the Centres for Disease Control and Prevention (CDC). 3.5 million Europeans a year contract an infection while in hospital. IGIN Global

2024-01-31 17:13 3028

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

* Global bioproduction leader 21st.BIO today announced it is now granting access to its precision fermentation technology platform to food and ingredient manufacturers, enabling sustainable production of dairy proteins at competitive cost.            * Access to 21st.BIO's technology represen...

2024-01-31 16:47 1772

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...

2024-01-31 10:43 3755

Synbio Tech's Innovative Probiotic Approach Revitalizes Gut and Vaginal Microbiota in Pregnant Women with Candidiasis

KAOHSIUNG, Jan. 31, 2024 /PRNewswire/ -- Innovative research and proprietary technologies have placed Synbio Tech, Inc. (1295:TT) at the forefront of the probiotics field. The company's advancements not only enhance probiotic production efficiency but also significantly benefit intestinal health,...

2024-01-31 09:00 3339

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) an...

2024-01-31 05:46 2694

Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results

JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its financial results for the fiscal year endedSeptember 30, 2023. Mr. Gang Lai, Chairman and C...

2024-01-31 05:30 3609

Medtec China's 20th Anniversary brings together 1000+ Exhibitors and Facilitates Business Innovation in Shanghai in September

SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- With the new favorable policy of encouraging the innovative development of advanced medical devices from the Guidance Catalogue for Industrial Structure Adjustment (2024), which announced by the National Development and Reform Commission , it indicates that...

2024-01-31 00:00 2408

The Biotech Accelerator Unicorn Program: A Unique Collaboration between CKGSB and the UC San Diego Rady School of Management

SAN DIEGO, Jan. 30, 2024 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) andUniversity of California San Diego (UC San Diego) Rady School of Management are proud to announce the launch of the Biotech Accelerator Unicorn Program, a pioneering joint program specifically designed to...

2024-01-30 22:25 2648

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 D...

2024-01-30 22:00 2247

XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...

2024-01-30 21:00 2681

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...

2024-01-30 18:05 1900

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology

JINAN, China, Jan. 30, 2024 /PRNewswire/ -- The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung can...

2024-01-30 16:45 2018

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

* The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor with excellent in vivo efficacy and safety profile in preclinical studies.  * This project fur...

2024-01-30 16:32 2442

MGI Unveils Comprehensive Expansion of Automation Product Lines for Life Science and Healthcare Research

The company will offer new and improved solutions for sample pre-treatment, sample preparation and integrated testing, leveraging its innovative technologies and expertise in genetic sequencing and multi-omics. SHENZHEN, China, Jan. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. (referred to as MGI...

2024-01-30 15:55 2620

Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...

2024-01-29 21:30 2043

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...

2024-01-29 21:08 2333

Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer

CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr.Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO). Dr. Wu brings with him more than three decades of experience in the field of...

2024-01-29 21:00 1629

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated withUtrecht University. This strategic ...

2024-01-29 21:00 2227
1 ... 269270271272273274275 ... 646